PTC Therapeutics, Inc. PTCT NASDAQ

PTC Therapeutics, Inc. (PTCT) reported total assets of $2.91B and total liabilities of $3.12B for fiscal year 2025, resulting in total equity of $-205.31M.

The company held $1.95B in cash and short-term investments. Total debt stood at $492.28M, with net debt of $-492.37M. The Debt-to-Equity (D/E) ratio was -2.4 (conservative).

Current ratio is 2.35, indicating strong short-term liquidity. Interest coverage is 5.6x (adequate).

Criteria supported by this page:

• HEALTH (75/100, Pass) — Debt-to-Equity of -2.4, current ratio of 2.35, interest coverage 5.6x — balance sheet is strong
• MOAT (74/100) — Total assets $2.91B and equity $-205.31M support the company's competitive scale
• VALUE (86/100) — Debt-to-Equity -2.4 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 74/100 with 5/7 criteria passed.

MDGL

Madrigal Pharmaceuticals, Inc.

$524.99

-0.13%

BPMC

Blueprint Medicines Corporation

$129.46

+0.14%

KRYS

Krystal Biotech, Inc.

$270.00

+0.97%

RETA

Reata Pharmaceuticals, Inc.

$172.36

+0.02%

VKTX

Viking Therapeutics, Inc.

$35.52

+1.46%

SRPT

Sarepta Therapeutics, Inc.

$22.15

+1.65%

IOVA

Iovance Biotherapeutics, Inc.

$3.64

+5.20%

ICPT

Intercept Pharmaceuticals, Inc.

$19.00

+0.21%